In practical terms, systemic administration of NGF has proven difficult to optimize, for instance, subcutaneous courses of rhNGF in diabetic polyneuropathy were technically feasible but ultimately failed to meet their primary efficacy endpoint and were consistently associated with injection-site hyperalgesia and pain. The gene discussed is NGF; the disease is diabetic polyneuropathy.